Green­Light Bio­sciences se­cures merg­er as it looks to go pri­vate

Green­Light Bio­science, the de­vel­op­er and man­u­fac­tur­er of RNA vac­cines and ther­a­peu­tics, is set to be ac­quired.

The com­pa­ny an­nounced ear­li­er this week that it would be ac­quired by a group of buy­ers led by Fall Line Cap­i­tal in a cash deal valu­ing Green­Light at around $45.5 mil­lion. Ac­cord­ing to a re­lease, Fall Line and the group agreed to ac­quire all of the shares of the com­pa­ny for $0.30 per share. The deal is ex­pect­ed to close some­time in the third quar­ter of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER